(1,3)-β-d-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial

Overview of attention for article published in Critical Care, September 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter: 38 X users

Citations

dimensions_citation: 35 Dimensions

Readers on

mendeley: 66 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 40 X posts from 38 X users, with an upper bound of 232,150 followers.

@LIM_3939 フルコナゾールを売ってた頃はβ-D-グルカンが治療効果の指標にならないのでその後は測定必要はないとしていました。一方でRCTでこんなのもあります。 https://t.co/mxQcw7T8FX

11 May 2024

Reply Repost Favourite

RT @ABsteward: 🔥Very Interesting🔥 A new single-centre open-label RCT n=108, β-D-Glucan-based empirical antifungal interruption in criticall…

30 Jun 2022

Reply Repost Favourite

RT @ABsteward: 🔥Very Interesting🔥 A new single-centre open-label RCT n=108, β-D-Glucan-based empirical antifungal interruption in criticall…

30 Jun 2022

Reply Repost Favourite

Excellent editorial @yourICM for CandiSep RCT Is (1,3)-β-D-glucan useless to guide antifungal therapy in ICU? 🌟Excellent figure🌟👇 A pragmatic approach for empirical antifungal treatment strategy #IDTwitter #medtwitter #TwitteRx #MedEd https://t.co/UfAfvSGh

30 Jun 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 36 additional X posts.